Market Overview

Alnylam Pharma Reports Offering of $125M in Stock

Related ALNY
Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV For The Treatment Of Chronic Hepatitis Delta Virus Infection And ALN-PDL For The Treatment Of Chronic Liver Infections
Alnylam Completes Phase 2 Enrollment
Action in Ebola-Related Stocks (Fox Business)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $125 million. All of the shares in the offering are to be sold by Alnylam.

Posted-In: News Offerings


Related Articles (ALNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters